BLOG
If you’re a lean biopharma team heading toward IND or your first clinical trial, choosing the right bioanalytical partner for biopharma startups is one of the highest-stakes decisions you’ll make, and it has nothing to do with your molecule. It’s about who generates your PK, PD, and biomarker data, and whether that data holds up under regulatory scrutiny.
Get it right, and your timelines stay intact while your team spends its limited hours on science instead of vendor management. Get it wrong, and you’re re-running assays, re-explaining your program to a new lab, or discovering a method gap three weeks before a filing deadline.
Four ways to structure your bioanalytical support
There isn’t a single “best” bioanalytical CRO. The right fit depends on your stage, modality, budget, and how much bioanalytical expertise you already have in-house. Most startups end up choosing between four approaches.
1. One integrated partner across phases
A single bioanalytical CRO supports you from discovery through late-phase clinical, ideally with global lab capacity so you’re not renegotiating a new relationship every time your program moves regions or phases. Fewer handoffs, one quality standard, one team that already knows your molecule’s history.
2. A network of specialists
You select a different, best-in-class lab for each technique: LC-MS/MS here, immunogenicity there, biomarkers somewhere else. This can deliver deep technical excellence per workstream, but it demands real internal bandwidth to manage multiple vendors, multiple data formats, and the handoff risk between them.
3. A hybrid model
One core partner for the bulk of the work, supplemented by specialist support for a narrow technical gap. Common for teams with some internal program leadership but not enough to run a full multi-vendor network.
4. A single one-stop shop for everything
Some smaller biotechs want one partner covering not just bioanalytics, but clinical operations and central lab as well. It’s an understandable instinct, fewer contracts, one point of contact, but no single organisation is genuinely best in class across all three. Optimising for one relationship over geographical alignment, specific capability, capacity, communication, and experience usually costs more than it saves, particularly once time zone differences start working against your study timelines. We partner closely with dedicated clinical and central lab specialists and can make the right introductions, but we would never be the one driving your entire study or program.
Why one bioanalytical partner for biopharma startups usually wins
For most startups, the maths favours the integrated model. You don’t have a dedicated vendor management function.
You need speed to IND, not the marginal technical edge of stitching together five relationships. And every handoff between labs is a place where context, and time, gets lost.
That’s the case for consolidation in principle. In practice, not every “integrated” CRO earns the label. Here’s what actually separates a genuine bioanalytical partner for biopharma startups from a lab that simply has a long capability list.
5 criteria for choosing a bioanalytical partner for biopharma startups
1. Modality fit
Has this lab recently validated methods for your specific molecule type: oligonucleotide, ADC, biologic, small molecule, cell and gene therapy? Recent, relevant experience matters more than a long capability list. Ask for a comparable case study, not a generic capabilities deck.
2. Global reach
If your trial moves from Phase I in one region to Phase II/III in another, can the same partner follow you, with one quality standard, rather than forcing a re-validation with a new lab? Resolian, for example, runs labs across the US, UK, Australia, and China under one quality system, so a program can move regions without moving vendors.
3. Regulatory credibility
Is the data FDA, EMA, and MHRA inspection-ready from day one? The FDA’s bioanalytical method validation guidance sets the bar most sponsors are held to, so your partner needs to meet it as standard practice, not as an afterthought.
4. Capacity and timelines
A lab with the right capability on paper but no real slot for your study timeline isn’t a partner, it’s a bottleneck. Ask directly about current queue times for your assay type before you sign anything.
5. Data and communication
Can they give you standardised, submission-ready data, and are they proactive about flagging issues before they become your problem? The best partners tell you about a problem before you ask.
The bottom line
If you’re small and speed-constrained, a single bioanalytical partner for biopharma startups that spans your full development path, with genuine global lab infrastructure and inspection-ready data, will usually get you to the clinic faster and with less internal overhead than managing a specialist network yourself.
Resolian works this way by design: one bioanalytical and analytical sciences partner across labs in the US, UK, Australia, and China, so startups get global reach without giving up a single quality standard or a single point of accountability.
Ready to talk through your program?
Talk to our bioanalytics team →
Frequently Asked Questions
What makes a bioanalytical CRO for global drug development suitable for a multi-country program?
A bioanalytical CRO for global drug development applies one quality standard across every lab in its network, so data generated in one country holds up the same way it would anywhere else. Genuine lab footprint in your trial’s regions matters more than a long list of certifications.
How many countries should a global bioanalytical CRO cover?
There’s no fixed number. What matters is whether the bioanalytical CRO has real lab capacity, not just subcontracting arrangements, in the specific regions your multi-country program will actually run in.
What's the biggest risk when choosing a bioanalytical CRO for global drug development?
The handoff between phases and geographies. If method transfer between your Phase I site and Phase II site requires re-validation from scratch, you lose time and risk data comparability, the opposite of what a strong bioanalytical CRO for global drug development should deliver.
